natgillin/translations-raw huggingface dataset:
TNF- alpha er en medvirkende årsag til betændelsestilstande og findes i høje koncentrationer hos patienter med de sygdomme, der behandles med Flixabi.
TNF-alpha is involved in causing inflammation and is found at high levels in patients with the diseases that Flixabi is used to treat.
TNF-antagonister, herunder Humira, er i sjældne tilfælde blevet forbundet med nyt udbrud eller forværring af kliniske symptomer og/eller radiografiske tegn på demyeliniserende sygdom i centralnervesystemet herunder dissemineret sklerose og optisk neurit og perifer demyeliniserende sygdom, inklusive Guillain-Barré syndrom.
TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-Barré syndrome.
TNF-antagonister, så som Humira påvirker immunsystemet og brugen af dem kan påvirke kroppens forsvar mod infektion og cancer.
TNF-antagonists, such as Humira affect the immune system and their use may affect the body’s defense against infection and cancer.
TNF-blokerende midler, inklusive Simponi, har i sjældne tilfælde været forbundet med nyopståede tilfælde af eller forværring af kliniske symptomer og/eller radiografiske tegn på demyeliniseringssygdomme i centralnervesystemet inklusive multipel sklerose og perifere demyeliniseringssygdomme.
Use of TNF-blocking agents, including Simponi, has been associated with cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and peripheral demyelinating disorders.
TNF-α er et vigtigt pro-inflammatorisk cytokin med en central rolle i inflammatoriske processer.
TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes.
To (2) patienter gennemgik angiveligt proceduren for hurtig elimimation, men resultatet var ukendt for begge patienter.
Two (2) patients underwent reportedly the rapid elimination procedure; however, the outcome was unknown for both patients.
To 10 mg kapsler
Two 10 mg capsules
To 10 mg kapsler plus en 4 mg kapsel
Two 10 mg capsules plus one 4 mg capsule
To 19-gauge, 50 mm Hypodermic sikkerhedskanyler
Two 19-gauge, 50 mm Hypodermic safety needles
To 20-mg hætteglas hver rekonstitueret med 1,2 ml solvens
Two 20-mg vials reconstituted with 1.2 mL solvent each
to 200 mg kapsler
two 200 mg capsules
To 320 mg/40 mg tabletter dagligt
Two 320 mg/40 mg tablets a day
To 4 mg kapsler
Two 4 mg capsules
To 400 mg kapsler (800 mg) –tre gange dagligt (hver 8. time).
Two 400 mg capsules (800 mg) - taken three times a day (every 8 hours).
To af de 14 ikke-behandlede forsøgspersoner, der deltog i tøj-over-hudkontakt-behandlingsgruppen, havde målbare plasmakoncentrationer af oxybutynin (Cmax <0,1 ng/ml) i 48 timer efter kontakt med de behandlede forsøgspersoner; oxybutynin var ikke detekterbart hos de resterende 12 ikke-behandlede forsøgspersoner.
Two of the 14 untreated subjects participating in the clothing-to-skin contact regimen had measurable oxybutynin plasma concentrations (Cmax < 0.1 ng/ml) during the 48 hours following contact with treated subjects; oxybutynin was not detectable with the remaining 12 untreated subjects.
To af de aktive stoffer i Broadline, eprinomectin og praziquantel, virker dræbende på parasitter, der lever inde i dyrets krop (endoparasitter).
Two of the active substances in Broadline, eprinomectin and praziquantel, act as ‘endoparasiticides’.
To af de aktive stoffer i Broadline, fipronil og (S)-methopren, virker dræbende på ydre parasitter (ektoparasitter).
Two of the active substances in Broadline, fipronil and (S)-methoprene, act as ‘ectoparasiticides’.
To af de aktive stoffer i Eviplera (tenofovirdisoproxil og emtricitabin) viser nogen aktivitet mod hepatitis B-virus.
Two of the active substances in Eviplera (tenofovir disoproxil and emtricitabine) show some activity against hepatitis B virus.
To af de fire personer havde nedsat nyrefunktion (dvs. estimeret kreatininclearance på under 70 ml/min) ved baseline.
Two of the four subjects had renal impairment (i.e. estimated creatinine clearance less than 70 mL/min) at baseline.
To af de otte tilfælde var ikke radiologisk bekræftet med MR-skanning.
Two of the eight cases did not have radiological confirmation via MRI.
To af de randomiserede patienter forlod i studiet før de fik studiemedicin
However two of the randomized patients discontinued the study before receiving any study treatment
To af studierne fandt ikke nogen forskel i risikoen for neuropsykiatriske indlæggelser hos vareniclinbrugerne sammenlignet med dem, der brugte nikotinplastre (hazard ratio [HR] 1,14; 95% konfidensinterval [CI]: 0,56-2,34 i det første studie og 0,76; 95% CI: 0,40-1,46 i det andet studie).
Two of the studies found no difference in risk of neuropsychiatric hospitalisations between varenicline users and nicotine patch users (Hazard Ratio [HR] 1.14; 95% Confidence Interval [CI]: 0.56–2.34 in the first study, and 0.76; 95% CI: 0.40-1.46 in the second study).
To af undersøgelserne omfattede patienter, der ikke tidligere var blevet behandlet for hiv:
Two studies involved patients who had not previously been treated for HIV:
To af undersøgelserne så nærmere på Invegas virkning på manisymptomer, og den tredje så nærmere på virkningen på depressionssymptomer.
Two studies assessed the effects of Invega on symptoms of mania whereas the third study assessed the effects on symptoms of depression..
To alkoholkompresser
two alcohol swabs
To andre hovedundersøgelser - én med 351 voksne og én med 207 børn (i alderen seks til 17 år) - vedrørte Zonegran som tillægsbehandling til eksisterende behandling.
Two other main studies, one involving 351 adults and one involving 207 children (between 6 and 17 years old), looked at Zonegran as an add-on to existing treatment.
To andre hovedundersøgelser sammenlignede Thymanax’ og placebos evne til at forhindre, at symptomerne kom igen, hos 706 patienter, hvis depression allerede var kontrolleret med Thymanax.
Two other main studies compared the ability of Thymanax and placebo to prevent symptoms returning in 706 patients whose depression had already been controlled with Thymanax.
To andre hovedundersøgelser sammenlignede Valdoxans og placebos evne til at forhindre, at symptomerne kom igen, hos 706 patienter, hvis depression allerede var kontrolleret med Valdoxan.
Two other main studies compared the ability of Valdoxan and placebo to prevent symptoms returning in 706 patients whose depression had already been controlled with Valdoxan.
To andre mindre, randomiserede, placebokontrollerede afprøvninger kunne ikke påvise nogen signifikant forbedring af livskvalitetsparametre på hhv.
Two other smaller, randomized, placebo-controlled trials failed to show a significant improvement in quality of life parameters on the EORTC-QLQ-C30 scale or CLAS, respectively.
To andre prospektive, randomiserede, kontrollerede kliniske langtidsundersøgelser (med 9.620 patienter, hver undersøgelse med en varighed på > 3 år), der sammenlignede rosiglitazon og andre godkendte orale antidiabetika eller placebo, hverken be- eller afkræfteder den potentielle risiko for myokardieiskæmi.
Two other long-term prospective randomised controlled clinical trials (9,620 patients, study duration >3 years in each study), comparing rosiglitazone to some other approved oral antidiabetic agents or placebo, have not confirmed or excluded the potential risk of cardiac ischaemia.
To andre undersøgelser af 101 patienter så nærmere på, hvor effektivt Kuvan var til at holde koncentrationen af fenylalanin i blodet på det ønskede niveau (dvs. tolerancen over for fenylalanin) hos de patienter, der spiste fødevarer indeholdende fenylalanin.
Two other studies in 101 patients looked at how effective Kuvan was at allowing the patients to consume foods containing phenylalanine while keeping blood phenylalanine at target levels (i.e. phenylalanine tolerance)
To andre undersøgelser vedrørte effektiviteten af Tivicay hos patienter, hvis tidligere hiv-behandling ikke længere virkede:
Two other studies looked at the effectiveness of Tivicay in patients whose previous HIV treatment had stopped working:
To andre undersøgelser vedrørte virkningen af Emtriva i kombination med andre antivirale midler og omfattede 120 hiv-inficerede patienter mellem 4 måneder og 18 år.
The effectiveness of Emtriva, in combination with other antiviral medicines, was also assessed in two studies including 120 HIV-infected patients aged between four months and 18 years.
To andre undersøgelser viste, at dapagliflozin, anvendt i 24 uger sammen med metformin og et andet sukkersygemiddel, sitagliptin eller insulin, nedsatte HbA1c endnu mere: Dapagliflozin-kombinationen nedsatte HbA1c-koncentrationen 0,40 % mere end placebo og metformin som tillægsbehandling til sitagliptin, og 0,61 % mere end placebo og metformin som tillægsbehandling til insulin.
Two other studies showed that dapagliflozin taken with metformin and another diabetes medicine, sitagliptin or insulin, for 24 weeks, further decreased HbA1c: the dapagliflozin combination decreased HbA1c levels by 0.40% more than placebo and metformin when added to sitagliptin, and by 0.61% more than placebo and metformin when added to insulin.
To andre undersøgelser viste, at dapagliflozin, anvendt i 24 uger sammen med metformin og et andet sukkersygemiddel, sitagliptin eller insulin, nedsatte HbA1c endnu mere: Dapagliflozin-kombinationen nedsatte HbA1c-koncentrationen med 0,40 % mere end placebo og metformin som tillægsbehandling til sitagliptin, og 0,61 % mere end placebo og metformin som tillægsbehandling til insulin.
Two other studies showed that dapagliflozin taken with metformin and another diabetes medicine, sitagliptin or insulin, for 24 weeks, further decreased HbA1c: the dapagliflozin combination decreased HbA1c levels by 0.40% more than placebo and metformin when added to sitagliptin, and by 0.61% more than placebo and metformin when added to insulin.
To asymptomatiske, lavtitrede, transiente inhibitorer blev set hos 94 patienter med en medianeksponering på 76 eksponeringsdage (ED, interval 1-92), svarende til 2,2 % af de 89 patienter med mindst 50 ED.
Two clinically silent, low-titre, transient inhibitors were observed in 94 patients with a median exposure of 76 exposure days (ED, range 1-92), corresponding to 2.2% of the 89 patients with at least 50 ED.
To børn på fluticasonpropionat/salmeterol og 5 børn på fluticasonpropionat udgik pga. forværring af astmaen.
Two children on fluticasone propionate/salmeterol and 5 children on fluticasone propionate withdrew because of worsening asthma.
To dobbeltblinde, randomiserede, placebokontrollerede studier hos voksne med BMI 28 kg/m2 understøtter virkningen af orlistat 60 mg, når det tages 3 gange daglig og kombineres med kalorie- og fedtfattig kost.
Two double-blind, randomised, placebo-controlled studies in adults with a BMI 28 kg/m2 support the efficacy of orlistat 60 mg taken three times daily in conjunction with a hypocaloric, lower-fat diet.
To doser af Versican Plus Pi med 3 til 4 ugers mellemrum fra 6-ugers alderen.
Two doses of Versican Plus Pi 3–4 weeks apart from 6 weeks of age.
To doser før 1-års alderen: 85 %
Two doses under age 1: 85
To doser på hver 0,5 ml.
Two doses each of 0.5 ml.
To doseringer af Paxene kan gives: Paxene 175 mg/m2 kropsoverflade givet som en 3 timers infusion i en vene, efterfulgt af et andet lægemiddel, cisplatin, hver tredje uge; alternativt Paxene 135 mg/m2 givet som en 24 timers infusion, efterfulgt af cisplatin, hver tredje uge.
Two doses of Paxene may be given: Paxene 175 mg/m2 of body surface area administrated as a 3 hour infusion into a vein, followed by another medicine, cisplatin, every three weeks; alternatively Paxene 135 mg/m2 given as a 24 hour infusion, followed by cisplatin, every three weeks.
To eller flere hjerneområder (hvert område er større end en enkelt kortikal gyrus), hvor der er reduceret eller manglende grå-hvid kontrast.
Two or more brain areas (each larger than a single cortical gyrus) in which there is reduced or absent grey-white contrast.
To eller tre injektioner på 90 µg pr. kg legemsvægt, der administreres med tre timers interval.
Two to three injections of 90 µg per kg body weight administered at three-hour intervals.
To fertilitetsundersøgelser med rotter viste påvirkning af den parentale generation (nedsat fødeindtag, langsommere kropsvægtforøgelse, savlen), men tolvaptan påvirkede ikke reproduktionsevnen hos hanrotter, og der sås ingen fosterpåvirkning.
Two fertility studies in rats showed effects on the parental generation (decreased food consumption and body weight gain, salivation), but tolvaptan did not affect reproductive performance in males and there were no effects on the foetuses.
To forsøg blev gennemført for at se, om TachoSil kunne bruges som vævsklæber.
Two studies were carried out to see if TachoSil could be used as a tissue sealant.
To forsøgspersoner kunne undvære parenteral støtte, mens de fik Revestive.
Two subjects were weaned off their parenteral support while on Revestive.
To forsøgspersoner, der var randomiseret til tenofovirdisoproxilfumarat, oplevede HBsAg-tab ved uge 240, men ikke serokonversion til anti-HBs.
Two subjects randomised to tenofovir disoproxil fumarate experienced HBsAg loss by Week 240, but not seroconversion to anti-HBs.
To første infusioner (ml/time)
First Two Infusion (ml/hour)
To første infusioner (ml/time)
First Two Infusions (ml/hour)
To gange daglig
Two times a day
To gange daglig Plasma hiv-1 RNA
Twice Daily Plasma HIV-1 RNA
To gange daglig.
Twice daily
to gange dagligt
daily)
to gange dagligt + Victrelis 800 mg
two times daily + Victrelis 800 mg
to gange dagligt gennem munden. sammen med et måltid for at undgå at få problemer med maven.
twice daily by mouth with meals to lower your chance of an upset stomach.
to gange dagligt) anvendes i
(600/100 mg twice daily) is used in
To gange før påbegyndelse af behandling
On two occasions prior to initiation of treatment
To gange ugentlig (N=78)
Twice weekly (N=78)
To Gelman ITLC-SG strips (2 cm x 10 cm)
Two Gelman ITLC-SG strips (2 cm x 10 cm)
To gennemsigtige doseringssprøjter medfølger.
Two measuring syringes are provided.
To genotoksicitets tests (in vitro muselymfom test og in vivo museknoglemarvs-mikronucleus- test) viste, at mycophenolatmofetil potentielt kan forårsage kromosomaberrationer.
Two genotoxicity assays (in vitro mouse lymphoma assay and in vivo mouse bone marrow micronucleus test) showed a potential of mycophenolate mofetil to cause chromosomal aberrations.
To graviditetstests (serum eller urin) med en sensitivitet på mindst 25 mIE/ml anbefales.
Two serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL are recommended; the second test should be performed
To hovedundersøgelser med Elocta viste, at lægemidlet er effektivt både til at forebygge og behandle blødningsepisoder.
Two main studies of Elocta showed that the medicine is effective at both preventing and treating bleeding episodes.
To hunde udviklede epistaksis, der ikke var associeret med trombocytopeni.
Two dogs developed epistaxis that was not associated with thrombocytopenia.
To hunde udviklede næseblod, som ikke havde forbindelse til nedsat antal af blodplader.
Two dogs developed epistaxis that was not associated with thrombocytopenia.
To hætteglas med Cinryze pulver skal rekonstitueres for at fremstille en dosis (1.000 enheder/10 ml).
Two vials of Cinryze powder must be reconstituted to make one dose (1000 Units/10 ml).
To hætteglas med Cinryze pulver skal rekonstitueres for at fremstille en dosis (1000 enheder/10 ml).
Two vials of Cinryze powder must be reconstituted to make one dose (1000 Units/10 ml).
To hætteglas med rekonstitueret Cinryze kombineres til en dosis (1000 enheder).
Two vials of reconstituted Cinryze are combined for one dose (1000 Units).
To hætteglas med rekonstitueret Cinryze kombineres til en enkelt dosis, svarende til en koncentration på 100 E/ml.
Two vials of reconstituted Cinryze are combined for a single dose, corresponding to a concentration of 100 U/ml.
To hætteglas med rekonstitueret Cinryze kombineres til én dosis (1000 enheder).
Two vials of reconstituted Cinryze are combined for one dose (1000 Units).
To in vivo fase 1-lægemiddel- interaktionsstudier har bekræftet trends i retning af øgede og sænkede trabectedin-eksponeringer ved administration sammen med henholdsvis ketoconazol og rifampicin.
Two in vivo drug-drug interaction phase 1 studies have confirmed trends toward increased and decreased trabectedin exposures when administered with ketoconazole and rifampicin, respectively.
To intermediatorer i fremstillingsprocessen, der også tilstede i det endelige produkt, er positive for mutagenese i Ames-testen.
Two intermediates of the manufacturing process, which are also present in the final product, are positive for mutagenesis in the Ames assay.
To kliniske fase III-forsøg blev gennemført med i alt 851 postmenopausale kvinder med avanceret brystcancer, som havde sygdomstilbagefald under, eller efter, adjuvant endokrin behandling, eller progression efter endokrin behandling for avanceret sygdom.
Two phase-III clinical trials were completed in a total of 851 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease.
To komponenter, nemlig raltegravir og raltegravir- glucuronid, påvistes i urinen og udgjorde henholdsvis cirka 9 % og 23 % af dosis.
Two components, namely raltegravir and raltegravir-glucuronide, were detected in urine and accounted for approximately 9 and 23 % of the dose, respectively.
To lægemidler er bioækvivalente, når de danner den samme mængde at det aktive stof i kroppen.
Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
To mellemstore (18)-gauge sterile kanyler til injektion
Two medium (18) gauge sterile injection needles
To metabolitter, hydroxyderivatet og carboxyderivatet, som formentlig er fremkommet under levermetabolismen (hovedenzymet er CYP2C9), blev identificeret både i urin og fæces.
Two metabolites – most probably resulting from hepatic metabolism (major enzyme is CYP2C9) – were identified both in urine and faeces: the hydroxy derivative and the carboxy derivative.
To metabolitter, monodesmethyl og N-oxid, blev påvist i lave koncentrationer i urinen.
Two metabolites, the mono-desmethyl and the N- oxide, were detected at low concentrations in the urine.
To mutationer gav en ændring på 7 til 8 gange i følsomheden over for abacavir, og kombinationer af tre mutationer var nødvendige for at give mere end en 8 gange ændring i følsomhed.
Two mutations conferred a 7 to 8 fold change in abacavir susceptibility and combinations of three mutations were required to confer more than an 8 fold change in susceptibility.
To måneders sputum-omdannelse (SCC) (dvs. fra vækst af Mycobacterium tuberculosis til ingen vækst i løbet af de første 2 måneder) observeret blandt de patienter, hvis dyrkning af sputum var positiv ved baseline, er opstillet i følgende tabel for behandlingsgrupper, der har fået delamanid plus OBR og placebo plus OBR:
Two-month sputum conversion (SCC) (i.e. growth of Mycobacterium tuberculosis to no growth over the first 2 months) observed among those patients who were sputum culture positive at baseline is tabulated below for the delamanid plus OBR and placebo plus OBR treatment groups:
To NRTI-forbundne mutationer
Any two NRTI- associated mutations
To NRTI-forbundne mutationer
Any two NRTI-associated mutations
To patienter (2/117, 1,7%), som brugte den fyldte pen s.c., oplevede lokale reaktioner på injektionsstedet.
Two patients (2/117, 1.7%) using the SC pre-filled pen experienced local injection site reactions.
To patienter i behandlingsarmen med 12-ugers LDV/SOF, en patient i behandlingsarmen med 12-ugers LDV/SOV + RBV, to patienter i behandlingsarmen med 24-ugers LDV/SOF og to patienter i behandlingsarmen med 24-ugers LDV/SOF+RBV havde ikke en bekræftet genotype 1-undertype.
Two patients in the LDV/SOF 12-week treatment arm, one patient in the LDV/SOF+RBV 12-week treatment arm, two patients in the LDV/SOF 24-week treatment arm, and two patients in the LDV/SOF+RBV 24-week treatment arm did not have a confirmed genotype 1 subtype.
To patienter i onkologiprogrammet fik en overdosis på højst 600 mg to gange daglig i op til otte dage.
Two patients in the oncology programme had an overdose of maximum 600 mg twice daily up to eight days.
To patienter med allerede eksisterende astma udviklede let til moderat åndedrætsbesvær i forbindelse med behandlingen (se afsnit 4.8).
Two patients with pre-existing asthma developed mild to moderate respiratory distress associated with the treatment (see section 4.8).
To patienter oplevede reaktioner på injektionsstedet, der førte til reduktioner af deres dosis af asfotase alfa.
Two patients experienced injection site reactions that led to reductions of their asfotase alfa dose.
To patienter ud af 3441, som blev behandlet med Humira i alle reumatoid artrit og psoriasisartrit studie, udviklede kliniske tegn, der tydede på et nyopstået lupuslignende syndrom.
Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis studies developed clinical signs suggestive of new-onset lupus-like syndrome.
To patienter ud af 3441, som blev behandlet med Humira i alle reumatoid artrit og psoriasisartrit-studier, udviklede kliniske tegn, der tydede på et nyopstået lupuslignende syndrom.
Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis studies developed clinical signs suggestive of new-onset lupus-like syndrome.
To patienter, en på placebo og en på ivacaftor seponerede permanent behandlingen som følge af forhøjede aminotransferaser, hver >8 x ULN.
Two patients, one on placebo and one on ivacaftor permanently discontinued treatment for elevated transaminases, each >8 x ULN.
To patienter, en på placebo og en på ivacaftor seponerede permanent behandlingen som følge af forhøjede aminotransferaser, hver >8 x ULN.
Two patients, one on placebo and one on ivacaftor, permanently discontinued treatment for elevated transaminases, each >8 x ULN.
To patienter, herunder den ene med et grad 3 tilfælde (tubulointerstitiel nefritis), fik højdosis kortikosteroid (i en dosis mindst ækvivalent med 40 mg prednison) med en median initialdosis på 0,8 mg/kg (0,5-1,2) og en median varighed på 5,3 uger (0,9-9,7).
Two patients, including the one patient with a Grade 3 case (tubulointerstitial nephritis), received high-dose corticosteroids (at least 40 mg prednisone equivalents) at a median initial dose of 0.8 mg/kg (range: 0.5-1.2) for a median duration of
To pivotale studier (SP512 del I og SP513 del I), som undersøgte rotigotins behandlingseffekt ved tegn og symptomer på idiopatisk Parkinsons sygdom blev udført med patienter, som ikke samtidig blev behandlet med en dopaminagonist, og som enten var levodopa-naive, eller hvor den tidligere levodopa-behandling varede ≤ 6 måneder.
Two pivotal trials (SP512 Part I and SP513 Part I) investigating the effectiveness of rotigotine in the treatment of the signs and symptoms of idiopathic Parkinson’s disease were conducted in patients who were not receiving concomitant dopamine agonist therapy and were either L-dopa naïve or previous L-dopa treatment was ≤ 6 months.
to plastre et stk. gazebind.
two plasters one gauze pad.
To polyethylen/polypropylen-målesprøjter, en 1 ml- og en 5 ml- sprøjte, leveres med hver flaske for at sikre en præcis dosering til både små og store hunde.
Two polyethylene/polypropylene measuring syringes, a 1 ml and 5 ml syringe, are supplied with each bottle to ensure accurate dosing of small and large dogs.
To polyethylen/polypropylen-målesprøjter, en 1 ml- og en 5 ml- sprøjte, leveres med hver flaske for at sikre en præcis dosering til både små og store hunde.
Two polyethylene/polypropylene measuring syringes, a 1 ml and a 5 ml syringe, are supplied with each bottle to ensure accurate dosing of small and large dogs.